Mutations in LRRK2 gene cause inherited Parkinson's disease (PD) and variations around LRRK2 act as risk factor for disease. Similar to sporadic disease, LRRK2-linked cases show late onset and, typically, the presence of proteinaceous inclusions named Lewy bodies (LBs) in neurons. Recently, defects on ceramide (Cer) metabolism have been recognized in PD. In particular, heterozygous mutations in the gene encoding for glucocerebrosidase (GBA1), a lysosomal enzyme converting glucosyl-ceramides (Glc-Cer) into Cer, increase the risk of developing PD. Although several studies have linked LRRK2 with membrane-related processes and autophagic-lysosomal pathway regulation, whether this protein impinges on the Cer pathway has not been addressed. Here, using a targeted lipidomics approach, we report an altered sphingolipid composition in Lrrk2 -/-mouse brains. In particular, we observe a significant increase of Cer levels in Lrrk2 -/-mice and direct effects on GBA1. Collectively, our results suggest a link between LRRK2 and Cer metabolism, providing new insights into the possible role of this protein in sphingolipids metabolism, with implications for PD therapeutics.
INTRODUCTION
Parkinson's disease (PD) is an incurable disorder of the nervous system that affects voluntary movements. It occurs as hereditary or sporadic condition that progressively impairs the functionality of dopaminergic neurons of the substantia nigra pars compacta and, at later stages, of other brain regions. Another pathological hallmark of PD is the presence of abnormal lipids and protein aggregates termed Lewy bodies (LBs) inside the nerve cells. The main constituent of these inclusions is an aggregated fibrillar form of α-synuclein (aS) [1] .
Sphingolipids are particularly abundant in the nervous system and play important roles in cell function under physiological conditions and during disease development and progression. Several studies have provided evidence that sphingolipid levels are often altered in neurodegenerative diseases [2] [3] [4] . Ceramides (Cer), components of all major sphingolipid species in the brain, were found to have a defective homeostasis in neurodegenerative disorders with LBs pathology, including PD [2, [5] [6] [7] . This class of lipids is generated by three pathways: i) the sphingomyelin hydrolysis that occurs at the plasma membrane, ii) the de novo synthesis taking place within endoplasmic reticulum (ER)/Golgi apparatus and iii) the salvage pathway in the endo-lysosomal compartment. Cer play a crucial role in the regulation of both intracellular and plasma membrane dynamics, and in the modulation of membrane protein activity and signaling [8] . Moreover, Cer modulate processes that involve intracellular organelles such as autophagy [9] or mitochondrial-mediated apoptosis [10] . Other lines of evidence link Cer balance to PD pathogenesis: first, mutations in GBA1 and SMPD1, encoding two enzymes that regulate the ceramide salvage pathway, cause inherited forms of lysosomal storage disorders (LSDs) characterized by LB inclusions and neurodegeneration [11, 12] and, second, common variants in these genes have been identified as risk factors for PD [13] .
LRRK2 is mutated in families with autosomal dominantly inherited PD, and common variations around LRRK2 act as susceptibility factors for the disease [14, 15] . LRRK2 is a large multi-domain protein exhibiting both GTPase and kinase activities, and the most common PD-linked G2019S mutation shows a three-fold increase in LRRK2 kinase activity both in vitro and in vivo [16, 17] . G2019S carriers exhibit a phenotype nearly indistinguishable from idiopathic PD, with a late onset and often with LBs pathology [18] . Accumulating evidence indicates that LRRK2 is associated with membrane compartments [19, 20] where it phosphorylates key proteins involved in membrane remodeling [17, 21, 22] and regulates different processes including autophagylysosome pathway [23] , vesicular trafficking and protein sorting [14, 24] . However, Lrrk2 -/-mice or rats show a normal dopaminergic system, with subtle or no alterations in the number of dopaminergic neurons and in the levels of striatal dopamine [25] .
Recently, a strong association among PD, the G2019S LRRK2 mutation and/or GBA1 mutations was documented [26] . Accordingly, altered GBA1 activity was measured in blood from LRRK2 G2019S carriers compared to non-carriers [27] . However, it is not known whether LRRK2 is directly or indirectly implicated in sphingolipid/ceramide metabolism and/or to GBA1 function. Here, we investigate whether LRRK2 impacts sphingolipid metabolism: using a targeted lipidomics approach, we look at the consequence of Lrrk2 knock-out on the sphingolipid composition in mouse brains. 
MATERIALS AND METHODS

Animals
Lipid extraction
Brains were collected from three male Lrrk2 +/+ and three male Lrrk2 -/-mice at 1 year of age. Lipid extraction was performed through a protocol optimized for sphingolipids. Brains were homogenized in ultra-pure water and incubated on ice. 3 mL Folch solution (chloroform:methanol 2:1 v/v) were added to the homogenate and the solution was sonicated for 15 min at 4 °C. Centrifugation at 16000g for 15 min at 4 °C followed to recover the liquid phase [28] . The extracted samples were dried using a rotary evaporator, dissolved in 150 µL HPLC-grade methanol (Sigma-Aldrich Co.) and stored in closed vials at -20 °C until analysis.
LC-MS analysis
The LC-MS measurements were carried out using a Shimadzu High Performance LC system (CBM-20
A, equipped with the binary pump LC-20AB, Italy) working in reversed phase with a Kinetex C18 column (100 Å pore size, 4.6 mm ID, 2.6 μm particle size, and 10 cm length, Phenomenex, Italy). The mobile phase was composed of solvent A, methanol:water (7:3 v/v) with 12 mM ammonium acetate, and solvent B, methanol with 12 mM ammonium acetate. The gradient elution program started with 70% B, reached 100% B in 45 min, and was maintained at 100% B for 20 min, at the steady flow rate of 1 mL/min.
The HPLC was combined with an Applied Biosystems API 3000 QQQ mass spectrometer equipped with an electrospray ion source. Each sample was injected twice (10 µL aliquots). Standard solutions were used to obtain the response factors needed to convert peak areas into molar quantities. The mass spectrometer was . Since the reversed-phase chromatography method we used did not allow to resolve the different glycosylated species, such as glucosyl-ceramides and galactosyl-ceramides [29] , they are all referred to as glycosyl-ceramides (Gly-Cer).
Lipidomics data analysis
The LC-MS chromatograms were integrated using the proprietary software (Analyst 1.4.2), and the obtained molar amounts were analyzed using R environment.
To directly compare sphingolipid levels across samples, their molar amounts were normalized to the total lipid content, to obtain molar fractions. This approach allowed us to take into account the different biomasses of the samples. To compare changes in ceramides chain length and/or unsaturation across samples, the molar fraction of each ceramide was normalized to the total amount of ceramide d18 and expressed as percentage.
Western blot
Mouse brains were homogenized as previously described [30] . 
GBA1 enzymatic activity
The GBA1 enzymatic assay on brain lysates was performed as described elsewhere [31] . GBA1 activity 
RESULTS
18:1 Cer level is increased in Lrrk2 -/-mouse brains
In order to evaluate whether LRRK2 is involved in the regulation of the sphingolipid metabolism in the brain, we compared Cer, Gly-Cer, sulfatide and SM levels from brains of Lrrk2 -/-mice to those in the control (Lrrk2
) mice through a targeted LC-MS based approach (n=3 brains per condition analyzed separately). Data were normalized to the total lipids content to account for the different sample biomasses. The results are summarized in Figure 1 , where the overall levels of identified sphingolipids in Interestingly, Cer, SM and sulfatides are all downstream of GBA1, while Gly-Cer, being partially constituted by Glc-Cer [29] , are upstream. Since in our experimental setup we could not separate Glc-Cer and Gal-Cer, we verified if a measurable effect on the overall Gly-Cer level in neurons could be obtained by inhibiting GBA1
using CBE. The results show that when GBA1 activity is reduced by about 80% through 50 μM CBE cronic treatment, a clear effect on the Gly-Cer level and on the Gly-Cer/Cer ratio can be appreciated in primary neurons (Supplementary Figure 1) . Therefore, we calculated the overall molar ratio [Gly-Cer]/[Cer] on in Lrrk2 -/-brains compared to controls. Figure 2 shows the comparison between samples and even though there is a clear trend, the difference is not significant. Taken together, these results point to an involvement of LRRK2 on Cer metabolism but further experiments are needed to verify a possible LRRK2-mediated dysregulation of GBA1.
LRRK2 deficiency does not affect the Cer fatty acyl chain composition
The relative amounts of different Cer species, as defined by their fatty acyl chain composition, regulate ceramide function in lipid membranes and signaling pathways and was found to be unbalanced in PD brain samples [5, 32] . To assess whether the observed increase of total 18:1 Cer in brains was specific to certain acyl chains, we compared their relative amounts across samples, as described in the Methods. As shown in Figure 3 , there are no significant differences between Lrrk2 +/+ and Lrrk2 -/-samples, and the intra-class profiles are indistinguishable. Collectively, our results suggest that whereas the total Cer amount is affected by Lrrk2 knockout, the intra-class Cer distribution is not perturbed.
Lrrk2 -/-mouse brains show alterations in GBA1 enzymatic activity
Considering GBA1 involvement in PD, we hypothesize that the detected imbalance in Cer levels might be due to (at least in part) a dysregulation of GBA1 activity in Lrrk2 -/-brains. To further explore the impact of LRRK2 on the regulation of GBA1, we measured GBA1 protein levels in Lrrk2 +/+ and Lrrk2 -/-brain lysates.
Unexpectedly, we observed a significant downregulation of GBA1 in Lrrk2 -/-brain lysates (Figure 4A-B; representative image of n=3 brains per condition; experiment repeated three times, 9 brains in total per condition, t-test). Next, to assess whether GBA1 activity is affected in Lrrk2 -/-mice, we performed in vitro GBA1 activity assays on Lrrk2 +/+ and Lrrk2 -/-brain lysates. To take into account the differences between total GBA1 amount in 
DISCUSSION
In the present study we used a targeted lipidomics approach to identify possible sphingolipid alterations in brain samples of knock-out compared to wild-type Lrrk2 mice. To achieve this, we performed targeted LC-MS measurements and focused on sphingolipids, whose alterations in brain tissue of PD patients have been previously reported [5] and have been associated with dysregulation in GBA1 level and activity [33] .
We first observed a significant increase in the relative amount of Cer, together with a modest, nonsignificant increase in SM and sulfatides, and a modest, non-significant decrease in Gly-Cer. These variations suggest that LRRK2 deficiency affects sphingolipid metabolism, particularly Cer, which are the direct products of the reaction catalyzed by GBA1 in lysosomes. Specifically, the lack of LRRK2 is associated with a significant increase in GBA1 product, hinting that LRRK2 may regulate GBA1. However, by computing the Gly-Cer/Cer ratios we observed no significant differences, suggesting that the effect (if any) is order of magnitude lower compared to those exerted by CBE treatment in cortical neurons, or that the presence of Gal-Cer in the overall Gly-Cer may mask a measurable decrease in the Gly-Cer and therefore in Gly-Cer/Cer ratio [34] . To test the possibility that GBA1 is directly affected by the lack of LRRK2, we measured GBA1 protein amount and GBA1 enzymatic activity in brain lysates. Our results show that while GBA1 protein levels are reduced in Lrrk2 -/-brains as compared to wild-type, GBA1 specific activity is increased, a finding consistent with the accumulation of Cer observed with the lipidomics approach.
Our data, together with the reported increase in GBA1 activity in the blood samples from LRRK2 G2019S patients [27] , further support the involvement of LRRK2 in GBA1 regulation and suggest that both the presence of LRRK2 and its kinase activity might be involved in Cer metabolism through GBA1 regulation. On the other hand, in idiopathic PD patients as well as in PD patients carrying GBA1 mutations and in GD patients, a decrease in GBA1 level is usually associated with a decrease in GBA1 activity [27, 33, [35] [36] [37] [38] [39] [40] (Table 1 ). The overall picture that emerges from this analysis is that Cer metabolism is important in PD etiopathogenesis. The association of abnormal GBA1 activity with PD, higher in LRRK2 G2019S patients and in LRRK2 deficient systems and lower in both GBA1 mutation carriers as well as sporadic PD patients without GBA1 mutations, may reflect a distinct pathogenic mechanism for LRRK2-linked PD that deserves further investigation.
Since LRRK2 functions as scaffold for several kinases and in the Wnt signalling by orchestrating their subcellular distribution and/or their interactions with upstream and downstream effectors [30, 41] , one possibility is that LRRK2 regulates GBA1 activity by affecting GBA1 localization, e.g. its delivery to lysosomes from the ER, which is controlled by lysosomal integral membrane protein type-2 (LIMP-2) [42] . Since an increase in GBA1 specific activity causes Cer accumulation, which we observed in Lrrk2 -/-brains, we suggest that a feedback mechanism may occur, leading to a reduction in GBA1 expression level. A decreased GBA1 level may be reached through an increase in its degradation rate or through the downregulation of GBA1 gene.
However, it is worth noting that also the other pathways involved in Cer regulation described in the introduction may be affected directly or indirectly by LRRK2 depletion.
To conclude, we propose that LRRK2 may play an important role in the sphingolipid metabolism, by affecting GBA1 regulation. Future studies are needed to confirm this link using independent models and to gain mechanistic insights into how LRRK2 regulates GBA1 function. Moreover, more needs to be done to understand if LRRK2 directly or indirectly regulates Cer metabolism through other pathways. Our results together with other recently published papers [2, 5, 7, 11, 27, 33] suggest that PD shares several features with sphingolipid disorders, opening new avenues for the identification of novel therapeutic strategies.
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